九源基因(02566)：JY47注射液新药临床试验申请获国家药监局临床试验默示许可

智通财经

Mar 17

智通财经APP讯，九源基因(02566)发布公告，集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可，适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。

该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体，可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用，SIRP拮抗剂可通过调节免疫细胞功能、改善组织微环境及代谢稳态，从而对代谢疾病进展产生积极影响。在MASH的体外类器官模型和体内疾病模型中，显示出良好的治疗潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620430440"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620430440\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620430440?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-17 17:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620430440","market":"hk","top_or_hot":-1,"title":"九源基因(02566)：JY47注射液新药临床试验申请获国家药监局临床试验默示许可","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02566\">九源基因</a>(02566)发布公告，集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可，适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。</p><p>该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体，可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用，SIRP拮抗剂可通过调节免疫细胞功能、改善组织微环境及代谢稳态，从而对代谢疾病进展产生积极影响。在MASH的体外类器官模型和体内疾病模型中，显示出良好的治疗潜力。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>九源基因(02566)：JY47注射液新药临床试验申请获国家药监局临床试验默示许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n九源基因(02566)：JY47注射液新药临床试验申请获国家药监局临床试验默示许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 17:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1414914.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，九源基因(02566)发布公告，集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可，适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体，可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414914.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1414914.html","article_id":"2620430440","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620430440","pubTimestamp":1773739274,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，九源基因(02566)发布公告，集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可，适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体，可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用，SIRP拮抗剂可通过调节免疫细胞功能、改善组织微环境及代谢稳态，从而对代谢疾病进展产生积极影响。在MASH的体外类器官模型和体内疾病模型中，显示出良好的治疗潜力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02566":"九源基因","BK1161":"生物科技"},"translate_title":"Jiuyuan Gene (02566): JY47 Injection New Drug Clinical Trial Application Obtained Implied Clinical Trial Permission from the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1.5},"content_text":"智通财经APP讯，九源基因(02566)发布公告，集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可，适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体，可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用，SIRP拮抗剂可通过调节免疫细胞功能、改善组织微环境及代谢稳态，从而对代谢疾病进展产生积极影响。在MASH的体外类器官模型和体内疾病模型中，显示出良好的治疗潜力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}